ImExHS Limited (ASX:IME)
Australia · Delayed Price · Currency is AUD | Market Cap | 18.92M -7.8% |
| Revenue (ttm) | 28.97M +9.2% |
| Net Income | -2.88M |
| EPS | -0.06 |
| Shares Out | 54.07M |
| PE Ratio | n/a |
| Forward PE | 16.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,312 |
| Open | 0.3550 |
| Previous Close | 0.3500 |
| Day's Range | 0.3500 - 0.3550 |
| 52-Week Range | 0.2200 - 0.4700 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 26, 2026 |
About ImExHS
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. The company operates in two segments: Software and Radiology. It offers medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company’s solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; and ANTEROS, a cardiology software solution.... [Read more]
Financial Performance
In 2025, ImExHS's revenue was 28.97 million, an increase of 9.17% compared to the previous year's 26.54 million. Losses were -2.88 million, 9.78% more than in 2024.
Financial StatementsNews
ImExHS Slides: FY 2026
ImExHS has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 19, 2026.
ImExHS Earnings release: Q1 2026
ImExHS released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
ImExHS Earnings Call Transcript: H2 2025
Revenue rose 10% to AUD 29 million and underlying EBITDA more than tripled to AUD 1.6 million, driven by strong ARR growth and operational improvements. FY 2026 guidance targets further EBITDA gains, cash positivity, and accelerated software revenue, with growth weighted to H2.
ImExHS Annual report: H2 2025
ImExHS has published its H2 2025 annual report on March 2, 2026.
ImExHS Slides: H2 2025
ImExHS has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 2, 2026.
ImExHS Earnings Call Transcript: Q3 2025
Q3 marked a financial turning point with ARR up 24% year-over-year and positive cash flow. AQUILA+ software and disciplined cost management drove margin gains, while new pricing segmentation and partner channels strengthened the pipeline. Guidance for FY revenue and EBITDA was reaffirmed.
ImExHS Earnings release: Q3 2025
ImExHS released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
ImExHS Slides: Q3 2025
ImExHS has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
ImExHS Earnings Call Transcript: H1 2025
Aquila Plus drove ARR growth with new wins in Colombia and Mexico, while revenue rose 4% year-on-year to $13.7 million and ARR reached $32.8 million, up 11%. FY2025 guidance projects revenue of $27.5–$28.2 million and EBITDA of $1.3–$1.6 million.
ImExHS Quarterly report: H1 2025
ImExHS has published its H1 2025 quarterly earnings report on September 1, 2025.
ImExHS Slides: H1 2025
ImExHS has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 1, 2025.